Cancer Registry Software Market Report Scope & Overview:

Get more information on Cancer Registry Software Market - Request Sample Report

Cancer Registry Software Market Size was valued at USD 76.6 Million in 2023 and is expected to reach USD 211.1 Million by 2032, growing at a CAGR of 11.9% over the forecast period 2024-2032. The cancer registry software market report delivers key statistical insights and adoption trends across hospitals, research centers, and government agencies along with user demographics by role, such as oncologists and data analysts. This looks at the expansion of cancer patient registries, the increase in data volume, and the uptake of cloud-based vs on-premise registries. It identifies trends in regulatory compliance and analyzes them in the context of standards such as HIPAA, GDPR and oncology. The report notes feature usage patterns, including a strong interest in analytics, AI-based analytics, automated EHR data entry, and EHR integration. Additionally, cost and investment trends provide insights into pricing models, funding patterns, and financial growth projections.

Market Dynamics

Drivers

• Growing prevalence of cancer and favorable government initiatives are driving the adoption of cancer registry software.

The growing incidence of cancer and favourable government initiatives is an important factors contributing to the increasing adoption of the cancer registry software. India sees up to 1.4 million newly diagnosed cases of cancer every year, a number which is expected to double by 2040 in keeping with the increasing burden of disease. Recent U.S. data show that close to six in ten of the 13 most common tumors are now being diagnosed at stages one or two, when they can be more effectively treated. Between September 2023 and August 2024, almost 121,000 out of 206,000 cancers diagnosed in England were found early.

The use of software for cancer registries is further being driven due to government initiatives. For example, the UK's NHS is trialing a service where women will be able to self-refer for breast cancer diagnostic tests via the NHS app, hoping to make diagnoses faster and reduce the reduce the burden on general practitioners. These advancements emphasize the impending necessity of well-functioning cancer registry systems to ease the growing tide of data, early detection of diseases, and subsequently, better treatment results. Using this software, healthcare providers can track cancer incidence, treatment, and survival more precisely guiding effective public health strategy and resource allocation.

Restraint:

• Privacy and data security-related concerns pose significant challenges to the adoption of cancer registry software.

Data security and patient privacy are some of the major issues affecting the Cancer Registry Software Market. Cancer registries collect personal information, which includes full name, address, Social Security number, and detailed medical histories. Such data is prone to identity theft, breaches, cyberattacks, and unauthorized access leading to a high potential for identity theft, criminal activities, and misuse of medical data. The U.S. Centers for Disease Control and Prevention (CDC) goes as far as to say that laxity in data security enables hackers to access data online, and that identity thieves often get data in low-tech ways through stealing laptops and/or storage media. In February 2024, the Kerala Cancer Registry was found to have scant protection of patient identities despite orders ensuring strict secrecy in the data collection process. This reflects the bigger picture of insufficient systemic data protection processes within cancer registers.

Opportunity:

• The growth of cloud-based cancer patient registry solutions presents significant opportunities for the market.

Cloud-based cancer registry solutions are coming up with high-growth opportunities in the healthcare sector. The reduced installation costs and lower IT overhead of the cloud/SAAS platform provide a major impetus for healthcare providers to go with such platforms. Cloud-based systems have an inherent benefit around real-time data analysis and integration using standard guidelines. These capabilities facilitate more efficient management of data and help to make effective and timely decisions while taking care of patients. For Example, Health Catalyst offers CRStar, a cloud-based cancer registry that minimizes startup time and total cost of ownership and provides internet accessibility from any computer.

In addition, cloud native solution offers high level of flexibility for integrating with other healthcare solutions to report information in one place. The integration is essential for patient outcomes tracking and quality of care improvement. With the trend of focusing on data security and interoperability in healthcare organizations, the demand for cloud-based cancer registry software will continue to grow and will offer scalable as well as efficient solutions to address the ever-changing landscape of cancer care management.

Challenge:

• Lack of interoperability and integration among different healthcare IT systems hinders the effective use of cancer registry software.

One key challenge to the implementation of cancer registry software is the lack of interoperability between healthcare IT systems. Coroners in England and Wales issued 36 warnings about the NHS failing to share patient information properly this year, blaming deaths on IT systems that could not communicate and limited access to medical records. For instance, a three-year-old boy with Down's Syndrome died because an NHS 111 adviser was unaware of his condition due to system incompatibilities.  In the United States, while there has been progress, challenges persist. A 70% of non-federal acute care hospitals are involved in sending, receiving, finding, and integrating patient health information across four domains of interoperability by 2023, up from 46% of hospitals in 2018. However, this indicates that 30% of hospitals still face challenges in fully integrating patient data.

Such interoperability problems result in fragmented patient information, miscommunication between healthcare providers, and other medical errors. This fragmentation can lead to incomplete data capture for cancer registry software, which depends on detailed and validated patient information for quality cancer surveillance and research. Resolving these interoperability problems is important so that cancer registry software can perform its best and contribute to better patient outcomes and cancer research.

Segment analysis

By Software

Standalone software dominated the market in 2023, accounting for 79% of the market share. This dominance is attributed to its advanced features, user-friendly interface, and ability to process registry data efficiently across multiple systems. Standalone software offers automatic upgrades, reducing IT overhead costs, which makes it highly appealing for healthcare providers. Additionally, its ability to support automated case registries and manage large-scale databases has made it a preferred choice among hospitals and government organizations. For example, tools like Web Plus streamline secure data transfers for state cancer registries like the Texas Cancer Registry. Government initiatives have further bolstered this segment's growth. The CDC's National Program of Cancer Registries (NPCR) provides technical assistance and funding for implementing such software in state registries, ensuring compliance with federal data standards. This support has improved data quality and timeliness, enabling better public health interventions.

By Deployment Model

On-premise model segment led the market, with a market share of about 59.8% in 2023. This large share of the market can be attributed to several factors, including data security concerns and the desire for end-to-end control of sensitive patient data. For example, U.S. regulations, including the Health Insurance Portability and Accountability Act (HIPAA) from the U.S. Department of Health and Human Services, and the Privacy Rule display the significance of maintaining security in cancer registries. Healthcare providers can maintain greater control over their data with on-premise solutions, establishing stricter security measures and making it easier to comply with these sorts of regulations. In addition, NPCR, a division of the Centers for Disease Control and Prevention (CDC), also funds states and territories to implement and maintain high-quality data records. These registries are generally data sensitive, so it's common for them to go on-premise to keep data integrity but also have easier integration with existing hospital information systems. The current prevalence of on-premise deployments can also be attributed to the Registry Plus suite of software developed by the CDC, which is widely used in central cancer registries and is specifically designed for on-premise deployment.

Moreover, the on-premise model also enables customization of applications and integration with existing legacy systems, which is necessary for larger healthcare institutions and government organizations with long-standing IT infrastructures. This flexibility and control have made on-premise solutions the preferred choice for many cancer registries, despite the growing trend towards cloud-based solutions in other areas of healthcare IT.

By Component

In 2023, the market was dominated by the commercial segment, capturing a market share of 75.0%. This substantial market share can be attributed to the advanced features, reliability, and comprehensive support offered by commercial cancer registry software solutions. The U.S. National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC) have set high standards for cancer data collection and management, which commercial software providers strive to meet and exceed. Commercial solutions often offer more sophisticated analytics capabilities, interoperability with other healthcare systems, and regular updates to comply with evolving regulatory requirements. For instance, National programs, like NPCR, have specifications for what central registries are expected to meet, and this is something commercial software can meet quite well. In addition, these solutions also provide good technical support and training to ensure that cancer registry data are accurate and complete.

In addition, commercial software vendors often perform product development with government laboratories and research centers. For example, the National Program of Cancer Registries of the CDC collaborates with software vendors to better align their products with NPCR data standards and reporting requirements. This synergy has produced the most strategically relevant and commercial value-driven products designed as direct responses to the unique requirements of cancer registries and has contributed to their overwhelming market success.

By Functionality

The Cancer Reporting to Meet State & Federal Regulations segment accounted for the largest market share in 2023 The key reason is actually because the government agencies have a strict set of reporting requirements. Central cancer registries in 46 states, the District of Columbia, and a few U.S. territories are required by the Centers for Disease Control and Prevention National Program of Cancer Registries (NPCR) to report standardized cancer data. Approximately, these registries include 97% of the U.S. population, making regulatory compliance in cancer reporting even more important. Cancer reporting with accuracy and timeliness is further highlighted by the collaboration between the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program and NPCR5. These programs generate statistics on cancer, so they also need software that can efficiently collect, process, and report data in a manner that complies with federal standards.

Additionally, NPCR-EDITS tools are provided by CDC to standardize how data validity checks are performed, to improve data quality. The focus on data standardization and quality control has increased the need for software and solutions that can cater to regulatory reporting needs. This has led to cancer registry software with classic reporting capabilities being critical for healthcare entities, as well as state agencies for regulatory compliance, and national cancer surveillance.

By end-use

The government & third-party segment dominated the market and accounted for a share of 26% in 2023. A major share of this market is due to the involvement of government agencies and third-party organizations in cancer surveillance and research. NPCR supports central cancer registries in 46 states and the District of Columbia plus U.S. territories that cover 97% of the U.S. population. Therefore, these registries, which are funded by the government, need sensitive software solutions to gather, manage, and analyze various cancer data accurately. Moreover, the NPCR partners with the National Cancer Institute to provide the SEER Program with combined national cancer data. Such collaboration between regional and government agencies requires advanced cancer registry software software, supporting a high accuracy and consistency of data between various regions.

This market segment includes significant contributions from third parties, including cancer research institutions and non-profit organizations. These organizations frequently collaborate with government institutions and healthcare professionals, implement cancer research, analyze treatment results, and create cancer control programs. Furthermore, this segment is also expected to witness high demand for highly specialized cancer registry software as the software used by these organizations should comply with federal and state regulations regarding data management and reporting.

Regional analysis

North America held the largest market share 43% of the cancer registry software market in 2023. A large share of this segment can be ascribed to the infrastructure for healthcare, the advanced setup of IT solutions for healthcare, & the better support from the government for the establishment of cancer surveillance programs in the region. The United States especially has been then leading the way with numerous cancer registry initiatives, including NPCR which measures 97% of the U.S. population through the Centers for Disease Control and Prevention (CDC).

During the forecast period, the fastest CAGR growth is anticipated for the Asia-Pacific region. The high growth rate during the forecast period is attributed to growing cancer incidence, increasing healthcare expenditure, and health acceptance of cancer registries in the region. According to the World Health Organization, the Asia-Pacific region accounted for nearly half of the global cancer burden in 2022, with approximately 9.5 million new cancer cases and 5.5 million cancer-related deaths. The study finds cancer control is gaining priority among many governments in the Asia-Pacific region who are investing in healthcare IT infrastructure. The Australian Government Cancer Australia initiative, for example, has been focusing on enhancing the national cancer data via the Australian Cancer Database, effectively pushing the use of cancer registry software across the country. Similarly, countries like Japan, South Korea, and China are extending their cancer registry programs, contributing to the region's rapid market growth.

Need Any Customization Research on Cancer Registry Software Market - Enquiry Now

Recent developments

• In February 2024, Radformation, Inc. partnered with Icon Group to advance cancer care by integrating innovative radiation oncology software, optimizing treatment workflows, and enhancing patient outcomes.

• In January 2025, The Centers for Disease Control and Prevention (CDC) announced updates to its Registry Plus software suite, introducing new features to improve data collection and processing for cancer registries. These updates aim to enhance the efficiency and accuracy of cancer data management across NPCR-funded central registries.

Key Players

Key Service Providers/Manufacturers

• C/NET Solutions (Cancer Registry Software, Oncolog)

• Elekta (METRIQ, MOSAIQ)

• McKesson Corporation (Horizon Clinicals, iKnowMed)

• IBM Corporation (Watson for Oncology, IBM Clinical Development)

• Siemens Healthineers (syngo.via, SOMATOM)

• Conduent, Inc. (Maven Disease Surveillance and Outbreak Management, Healthy Communities Institute)

• Electronic Registry Systems, Inc. (CRStar, ERS ePath Reporter)

• himagine solutions (Cancer Registry Services, HIM Services)

• NeuralFrame, Inc. (OncoLog Cancer Registry, NeuralFrame EHR)

• Onco, Inc. (OncoLog, OncoRegistry)

Users:

• National Cancer Institute (NCI)

• American Cancer Society

• Mayo Clinic

• Cleveland Clinic

• MD Anderson Cancer Center

• Johns Hopkins Medicine

• Memorial Sloan Kettering Cancer Center

• Kaiser Permanente

• U.S. Centers for Disease Control and Prevention (CDC)

• World Health Organization (WHO)